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Abstract
Purpose
Triple negative breast cancer (TNBC) patients frequently receive neoadjuvant chemother-
apy (NAC). Only 50% will achieve pathological complete response (pCR). In this retrospec-
tive study, we evaluated TNBC outcomes with NAC vs. AC.
Methods
Patients with stages II and III TNBC treated with NAC or AC between 2010 and 2013 were
identified from the National Cancer Database. Baseline characteristics were compared with
χ2 and two sample t tests. Kaplan-Meier survival analyses were computed in patients
treated with NAC or AC, and log-rank tests used to examine differences. Unadjusted analy-
ses of trends in proportions over time were performed using Cochran–Armitage tests. Log-
binomial models were applied to estimate relative risks of non-pCR following NAC.
Results
Of 19,151 patients, 5,621 (29.4%) received NAC, 13,530 (70.6%) received AC. NAC treated
patients had worse OS compared to AC treated patients (73.4% vs. 76.8%; p<0.0001). pCR
rate following NAC was 47.4%, and was associated with improved 5 year OS compared to
non-pCR (86.2% vs. 62.3%; p<0.0001). In patients who received NAC, age, black race, clin-
ical stage, diagnosis year, and Charlson-Deyo comorbidity score predicted non-pCR status.
Use of NAC increased over the study period from 2010 to 2013 (27.8% - 31.2%; p =
0.0002).
Conclusions
NAC may be inferior to AC in TNBC, likely related to the high frequency of non-pCR follow-
ing NAC. It is unclear if removing the primary tumor prior to chemotherapy will have a benefi-
cial biologic impact on therapeutic efficacy. These data should be considered hypothesis-
generating as it is possible that the findings are due to selection bias, as physicians may use
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NAC for TNBC patients with more advanced local disease. Although, NAC still has a role in
TNBC, developing biomarkers to identify patients likely to achieve pCR and benefit from
NAC is an urgent need.
Background
Breast cancer (BC) is the most commonly diagnosed malignancy in women. Approximately
266,120 new cases of invasive BC are estimated to be diagnosed in the United States in 2018
alone.[1] Although female BC is a leading cause of cancer mortality worldwide, it is often diag-
nosed at an early stage when it is potentially curable.[1] BC is biologically heterogeneous, with
different subtypes exhibiting different prognoses. Gene expression profiling has identified five
molecular subtypes with distinct behaviors and clinical outcomes: luminal A, luminal B, HER2
enriched, basal-like, and normal-like tumors.[2, 3] Basal-like tumors are predominately repre-
sented by the triple negative phenotype, characterized by the lack of estrogen receptor (ER),
progesterone receptor (PR), and HER2/neu oncogene. Triple negative breast cancers (TNBC)
account for 15–20% of all BC cases, are associated with a higher propensity for early recur-
rences, and have a worse 5 year overall survival (OS) compared with other BC subtypes.[4] In
a study from the National Cancer Database (NCDB), TNBC patients had distinct demographic
and racial/ethnic features as compared to non-TNBC patients.[5] TNBC is also associated with
a higher frequency in younger premenopausal women, a more aggressive phenotype, including
larger tumor size, higher tumor grade, but less likelihood of nodal involvement.[4, 6]
Although targeted therapies have improved management of ER-positive and HER2-positive
BC, cytotoxic chemotherapy remains the mainstay of systemic therapy for TNBC patients.
Despite worse prognosis, TNBC has higher response rates to chemotherapy.[7] Outcomes fol-
lowing neoadjuvant and adjuvant chemotherapy (AC) are comparable for BC patients in gen-
eral.[8, 9] Achieving pathological complete response (pCR), commonly defined by the lack of
invasive disease in the breast and axilla following neoadjuvant chemotherapy (NAC)
(ypT0N0), serves as an early surrogate of long-term prognosis. NAC facilitates tumor downsiz-
ing for breast-conserving surgery, also allows for in vivo assessment of response to therapy,
and provides prognostic information based on pathological response.[8] Another advantage of
NAC is to allow early use of systemic therapy to eradicate occult distant micrometastatic dis-
ease without delay. Our prior single-institutional studies have suggested that NAC may be
inferior to AC in TNBC in general, but is superior to AC only if pCR is achieved.[10, 11]
Patients who do not achieve a pCR with NAC have worse outcomes with higher locoregional
and systemic failure.[12–14] The administration of NAC has increased over time, with TNBC
and HER2-positive patients having the highest increases over time.[15, 16] This study was
designed to determine survival outcomes in TNBC patients treated with NAC vs. AC in a large
United States oncology database. We also explore trends in the use of NAC for TNBC.
Methods
Established in 1989, the NCDB is a joint national project of the Commission on Cancer of the
American College of Surgeons and the American Cancer Society. This database is sourced
from hospital registry data collected in Commission on Cancer accredited facilities. De-identi-
fied data provided by the NCDB was downloaded in May 2017. As NCDB data was not col-
lected for the purposes of this study and is de-identified, this study was not considered to meet
federal definitions under the jurisdiction of an Institutional Review Board, therefore an
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exemption was obtained. This article does not contain any studies with animals performed by
any of the authors. All procedures performed in studies involving human participants were in
accordance with the ethical standards of the institutional and/or national research committee
and with the 1964 Helsinki declaration and its later amendments or comparable ethical stan-
dards. IRB approval not applicable as deemed not human subject’s research (HSR) by Wash-
ington University School of Medicine.
We performed a retrospective analysis of adult patients with AJCC7 clinical stages II and III
TNBC who received systemic chemotherapy, and were diagnosed between 2010 and 2013.
Only tumors that were known to be ER, PR, and HER2 negative were included as TNBC.
HER2 status was recorded in the NCDB beginning in 2010, providing rationale for excluding
patients diagnosed prior to 2010. We excluded patients diagnosed after 2013 to allow for at
least 1 year survival period post diagnosis.
Demographic, socioeconomic, clinico-pathological features, treatment facility type, and
geographic location, were included in the analyses. Treatment facility types were noted as fol-
lows: Community Cancer Program, Comprehensive Community Cancer Program, Academic/
Research Program (includes NCI-designated comprehensive cancer centers), Integrated Net-
work Cancer Program, or other/unknown types of cancer programs. These were grouped as
academic programs (as defined by NCDB) vs. non-academic programs (all other treatment
facility types not defined as academic/research program by NCDB). NCDB defines pCR as the
absence of residual disease in the breast and lymph nodes following neoadjuvant
chemotherapy.
Patients with non-invasive disease, stage I TNBC, distant metastases, inflammatory BC,
missing treatment history or vital status (dead or alive), and patients who were not treated
with chemotherapy were excluded. In order to ensure that only TNBC patients were repre-
sented, those who received treatment with hormone therapy or immunotherapy were
excluded. Those with unknown pathological response status were also removed from the study
population.
Chemotherapy timing was determined by identifying the sequence of systemic treatment
and surgical procedures. Patients who received systemic therapy prior to surgery were defined
as having received NAC. Patients who had surgery followed by systemic therapy were defined
as having received AC. Patients who received both NAC and AC were also excluded. The
median follow-up was the median time between diagnosis and the date of last contact or
death.
Baseline sociodemographic and clinical characteristics across treatment type (NAC vs. AC)
were evaluated by using Mantel-Haenszel χ2 test for categorical variables and two sample t test
for continuous variables. The overall survival (OS) was defined as the interval between diagno-
sis and the date of death. OS by timing of chemotherapy receipt relative to surgery (NAC vs.
AC) and by pCR status post NAC was assessed. Survival curves were estimated by the Kaplan-
Meier method, and a two-sided P value of 0.05 from a log-rank test was considered a statisti-
cally significant difference. Five year OS rate (with 95% CI) was calculated by binomial
method. The log-rank test was used to examine the statistical significance of the differences
observed between the groups. Unadjusted analyses of trends in proportions over time were
performed using Cochran–Armitage trend tests. Trends in receipt of NAC vs. AC were exam-
ined during each of the 4 years (2010–2013). Predictors of non-pCR after NAC, including age,
race, income, education, insurance type, tumor grade, clinical stage, treatment facility type,
diagnosis year, and Charlson-Deyo comorbidity score were assessed using a Log-binomial
model and the results reported with adjusted relative risk of non-pCR and 95% confidence
intervals (CI). 2-sided P<0.05 was considered statistically significant. All analyses were per-
formed using SAS (version 9.4; SAS, Cary, NC).
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Results
After all exclusions, 19,151 patients met the study inclusion criteria (Fig 1). The median age of
the study population was 54 years (range: 21–90 years). 13,768 (71.9%) patients were White,
and 4,463 (23.3%) were Black. 83.5% of had clinical stage II disease, and 16.5% had stage III
disease. The majority of patients had poorly differentiated tumors (82.4%). Patient characteris-
tics by timing of chemotherapy receipt (NAC vs. AC) are summarized in Table 1. Of patients
receiving NAC, 68.4% had clinical stage II disease and 31.6% had stage III disease. The mean
age of patients who received NAC was 51.9 years, vs. 55.7 years in those who received AC
(p<0.0001). As compared with patients treated with AC, patients treated with NAC were more
likely to have private insurance (64.3% vs. 58.2%) and live in a metropolitan area of the United
States (88.2% vs. 84.1%). Patients were more likely to receive NAC at an academic program
(33.4%), as compared to if treated at a non-academic program (25.4%) (p<0.0001).
At a median follow-up of 35.8 months, the 5 year OS of all patients was 75.8% (95% CI,
74.9–76.7%). OS was inferior in TNBC patients treated with NAC, than those treated with AC
(73.4% [95% CI, 71.6–75.1%] vs. 76.8% [95% CI, 75.7–77.8%] p<0.0001) (Fig 2). Amongst the
Fig 1. Patients with breast cancer in the NCDB data set included in the analytical cohort. . Patients from the NCDB data set that were included in the analytical
cohort. Abbreviations: NCDB, National Cancer Database; TNBC, triple negative breast cancer; AC, adjuvant chemotherapy; NAC, neoadjuvant chemotherapy, pCR,
pathologic complete response.
https://doi.org/10.1371/journal.pone.0222358.g001
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Table 1. Patient characteristics according to treatment group.
Characteristic Group NAC (N /%) Group AC (N /%) P-Value
Age, mean (SD) 51.9 (11.8) 55.7 (12.4) <0.0001
Race 0.3874
White 4007 (71.9) 9761 (72.6)
Black 1343 (24.1) 3120 (23.2)
Other 224 (4.0) 564 (4.2)
Clinical Stage <0.0001
II 3843 (68.4) 12142 (89.7)
III 1778 (31.6) 1388 (10.3)
Grade 0.0001
Well-differentiated 26 (0.5) 102 (0.8)
Moderately-differentiated 649 (12.5) 1328 (10.4)
Poorly-differentiated 4530 (87.0) 11391 (88.8)
Charlson-Deyo Score <0.0001
0 4913 (87.4) 11128 (82.3)
1 598 (10.6) 1953 (14.4)
2 110 (2.0) 449 (3.3)
Insurance Type <0.0001
No insurance 215(3.9) 454 (3.4)
Private Insurance 3637 (64.3) 7780 (58.2)
Medicaid 734 (13.2) 1427 (10.7)
Medicare 911 (16.4) 3522 (26,3)
Other Government 68 (1.2) 192 (1.4)
Percentage with high school degree <0.0001
�21% 953 (17.0) 2516 (18.6)
13–20.9% 147 (26.3) 3728 (27.6)
7–12.9% 1757 (31.4) 4272 (31.7)
<7% 1418 (25.3) 2975 (22.1)
Median Income Quartiles <0.0001
Less than $38,000 1006 (18.0) 2624 (19.5)
$38,000 - $47,999 1186 (21.2) 3206 (23.8)
$48,000 - $62,999 1515 (27.1) 3545 (26.3)
� $63,000 1892 (33.8) 4111 (30.5)
Geographic Location <0.0001
New England 238 (5.0) 559 (4.6)
Middle Atlantic 595 (12.6) 1651 (13.5)
South Atlantic 1329 (28.1) 3169 (26.0)
East North Central 842 (17.8) 2377 (19.5)
East South Central 292 (6.2) 988 (8.1)
West North Central 343 (7.3) 821 (6.7)
West South Central 391 (7.3) 900 (7.4)
Mountain 207 (4.4) 547 (4.5)
Pacific 488 (10.3) 1177 (9.7)
Urban/Rural <0.0001
Metro 4842 (88.2) 11133 (84.1)
Rural 70 (1.3) 235 (1.8)
Urban 573 (10.5) 1865 (14.1)
Treatment Facility Type <0.0001
(Continued)
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5,621 patients treated with NAC, 2,664 achieved pCR (47.4%). Advanced age, Black race, and
clinical stage III disease were all associated with a higher risk of having a non-pCR to NAC
(Table 2). Achieving pCR following NAC was associated with significantly improved OS as
compared to lack of pCR, with a 5 year OS rate of 86.2% (95% CI 83.6–88.5%) for pCR, vs.
62.3% (95% CI 59.8–64.7%) for non-pCR, respectively (p<0.0001) (Fig 3).
Next, we evaluated time trends in timing of chemotherapy relative to surgery, and trends in
setting of care. NAC use increased over the study period (27.8% in 2010, 28.8% in 2011, 29.7%
in 2012, and 31.2% in 2013; p = 0.0002) (Fig 4). Receiving treatment at an academic program
did not change during the study period (30.4% in 2010, 31.1% in 2011, 32.8% in 2012, and
31.6% in 2013, p = 0.095). There was a difference in 5 year OS between patients treated at an
academic program as compared to a non-academic program, 77.0% vs. 74.3% (p = 0.003). In
the subset of patients receiving NAC, there was no difference in 5year OS by treatment facility
type (p = 0.063).
Discussion
This study aimed to determine the overall survival for TNBC patients treated with NAC vs.
AC in a multi-institutional cohort of United States breast cancer patients. To achieve this aim,
we analyzed 19,151 TNBC patients from the NCDB. To our knowledge, this is the largest study
evaluating the impact of chemotherapy timing on survival in TNBC patients treated with cura-
tive intent. Our study demonstrates that TNBC patients had a worse survival with NAC as
compared to AC. These findings are in contrast to NSABP B-18, EORTC 10902, and the
IBBGS, three large randomized trials evaluating NAC vs. AC.[8, 17, 18] These trials showed
that there was no difference in survival among breast cancer patients receiving NAC compared
to those receiving AC. However, there was no selection according to BC clinical subtype in
these earlier studies. Other prior studies have shown conflicting results in outcomes specifi-
cally for TNBC patients treated with NAC vs. AC.[10, 19] Prior data from our institution show
that NAC is superior to AC, only in TNBC patients who achieve pCR.[8] The pCR rate in this
present study was 47.4%. This study confirmed a strong survival advantage with NAC in
patients who achieve pCR also observed in other studies.[12, 20, 21] The differential outcome
based on timing of chemotherapy relative to surgery is likely because of the high frequency of
patients who did not achieve pCR with NAC seen in this study. TNBC patients who do not
achieve pCR have a very high risk of disease relapse and subsequent BC-related deaths.
Another important observation is the long-term outcome in patients with pCR. TNBC and
HER2-positive BC patients who achieve a pCR to NAC have a good prognosis.[12] The
Table 1. (Continued)
Characteristic Group NAC (N /%) Group AC (N /%) P-Value
Academic Program 1777 (37.6) 3547 (29.1)
Non-Academic Program 2948 (62.4) 8642 (70.6)
Diagnosis Year 0.0027
2010 1332 (23.7) 3456 (25.5)
2011 1459 (26.0) 3613 (26.7)
2012 1381 (24.6) 3264 (24.1)
2013 1449 (25.8) 3197 (23.6)
Variables according to treatment group. Data are presented as No. (%) unless otherwise noted. Age as mean
(standard deviation), defined in years. Abbreviations: NAC, neoadjuvant chemotherapy; AC, adjuvant
chemotherapy; SD, standard deviation.
https://doi.org/10.1371/journal.pone.0222358.t001
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improvement in outcomes pCR patients relative to non-pCR patients in this current study is
consistent with the improvements in OS and event-free survival in pCR patients in other stud-
ies.[22–24] Although pCR patients have superior outcomes than non-pCR patients, a number
of those with pCR still have disease recurrence and BC-related deaths. There is no reliable
method for detecting residual systemic microscopic disease after curative treatments, and to
date, no risk factors for recurrence have been identified in either pCR or non-pCR patients.
The potential to individualize management on the basis of prognostic markers remains an
unmet need, and tools to predict disease recurrence are lacking. If patients who will recur due
to chemotherapy resistance can be identified much earlier, innovative clinical trials can be
developed, with a view to changing the natural history of recurrent TNBC.
Fig 2. Kaplan-Meier estimates of overall survival in TNBC patients treated with NAC versus AC. OS rates presented as (%, 95% CI). OS rate was
significantly superior for patients receiving AC versus NAC, 76.8% (75.5–77.8%) versus 73.4% (71.6–75.1%), P-value<0.0001. Abbreviations: CI,
confidence interval; TNBC, triple negative breast cancer; OS, overall survival; AC, adjuvant chemotherapy; NAC, neoadjuvant chemotherapy.
https://doi.org/10.1371/journal.pone.0222358.g002
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Lastly, this study confirms the previously described increased trend in the use of NAC in
TNBC patients.[16, 25] TNBC patients are more likely to respond to NAC than patients with
Table 2. Predictors of pathologic complete response following NAC.
Variable No. events (pCR / total) RR 95% CI
Age 1.009 1.006–1.012
Race P = 0.044
White 2054/4007 Ref
Black 767/1343 1.087 1.025–1.153
Other 113/224 1.001 0.866–1.157
Grade P <0.0001
Well-differentiated 16/26 Ref
Moderately-differentiated 409/649 1.008 0.742–1.369
Poorly-differentiated 2349/4490 0.868 0.641–1.175
Undifferentiated 16/40 0.745 0.465–1.196
Clinical Stage <0.0001
2 1888/3843 Ref
3 1069/1778 1.175 1.115–1.238
Insurance Type P = 0.9627
No insurance 16/215 Ref
Private insurance 1780/3637 0.899 0.789–1.024
Medicaid 421/734 1.015 0.881–1.168
Medicare 570/911 0.944 0.819–1.089
Other Government 34/68 0.869 0.650–1.159
Facility Type P = 0.5575
Non-academic 1589/2948 Ref
Academic 947/1777 0.984 0.932–1.039
Diagnosis Year P = 0.0082
2010 746/1332 Ref
2011 784/1459 0.958 0.895–1.026
2012 692/1381 0.902 0.839–0.968
2013 735/1449 0.923 0.859–0.991
Percentage with high school degree P = 0.6151
� 21% 516/953 Ref
13–20.9% 797/1471 1.004 0.923–1.091
7–12.9% 916/1757 1.008 0.917–1.107
<7% 711/1418 1.000 0.896–1.117
Income P = 0.4872
Less than $38,000 558/1006 Ref
$38,000 - $47,999 615/1185 0.984 0.902–1.075
$48,000 - $62,999 820/1515 1.063 0.971–1.164
� $63,000 947/1892 0.966 0.869–1.073
Charlson-Deyo Score P = 0.0102
0 2535/4913 Ref
1 353/598 1.079 1.005–1.158
2 69/110 1.109 0.981–1.254
Variable that predict pCR in TNBC patients. Data presented as: Number of pCR events/total events, RR and 95% CI,
as compared to the reference variable. Abbreviations: NAC, neoadjuvant chemotherapy; pCR, pathologic complete
response RR, Relative risk; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0222358.t002
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ER-positive BC, thus NAC is now recommended as part of guidelines for managing TNBC
patients with early-stage or locally-advanced disease.[26] Clinicians may be managing patients
with more guideline-concordant care.[27] The rise in the number of neoadjuvant trials in
TNBC is supported by the ability to assess in vivo responses to cancer therapeutics, and enables
a platform for biomarker exploration. Thus, neoadjuvant trials have accelerated drug discov-
ery, and have allowed clinicians to routinely administer NAC as standard of care. Achieving
breast conservation by tumor downstaging, and improving cosmesis are also important advan-
tages of NAC. Knowledge of pathological response to NAC also provides an opportunity to
adjuvant therapy and enroll high-risk patients onto clinical trials.[28] Despite these numerous
advantages of NAC over AC, there is a critical need to develop predictive biomarkers that can
accurately identify patients likely to achieve pCR, and who are consequently better suited for
Fig 3. Kaplan-Meier estimates of overall survival in TNBC patients achieving pCR versus non-pCR following NAC. OS rates presented as (%,
95% CI). 5-year OS rate was significantly superior with pCR versus non-pCR following NAC in TNBC patients 86.2% (83.6–88.5%) versus 62.3%
(59.8–64.7%), P-value<0.0001. Abbreviations: CI, confidence interval; TNBC, triple negative breast cancer; pCR, pathologic complete response.
https://doi.org/10.1371/journal.pone.0222358.g003
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NAC. Patients not likely to achieve pCR with standard NAC may then be enrolled onto inno-
vative trials, be spared unnecessary side effects of ineffective cytotoxic chemotherapy, or avoid
delaying definitive and potentially curative surgery.
This data must be interpreted in the light of its limitations. First, the analytic cohort was
restricted to those diagnosed between 2010 and 2013. The NCDB started collecting HER-2 sta-
tus in 2010; therefore, patients diagnosed prior to 2010 were excluded. This study period limits
appreciating full trends in the use of NAC and long-term outcomes. Nonetheless, the median
follow up of 3 years may allow an acceptable duration to evaluate outcomes in TNBC, as this
subtype has a higher propensity for early recurrence following diagnosis. Second, lack of spe-
cific chemotherapy data is also another limitation of this study. However, since the study
spanned a narrow, but contemporary period, we do not suspect that there were any substantial
differences in the types of chemotherapy regimens utilized. Third, data regarding genomic
testing (i.e. BRCA germline testing) were not available for analyses, however, these data do not
impact outcome in TNBC patients receiving NAC vs. AC.[19, 29] Patients with BRCA-associ-
ated TNBC with chemoresistant disease may benefit from targeted treatments with agents
such as PARP inhibitors as has been shown in the advanced setting.[30, 31] Fourth, retrospec-
tive analyses of observational data may be subjected to selection biases and unmeasured con-
founders. Immortal time bias is a limitation, as patients in the reference group had to be alive
to receive AC, which would have been several weeks after those who received NAC. Fifth,
although nodal status is prognostic in TNBC patients, it was not included in the analysis as
accurate assessment of clinical nodal status and/or number of nodes involved from a registry
Fig 4. Trends in use of NAC and treatment facility type over time in TNBC patients. Cochrane-Armitage Trend test for treatment type (NAC vs
AC) P-value 0.0002, and treatment facility type (academic vs non-academic program) P-value 0.095 used to determine trends over study period.
Data presented by percent (%) of TNBC patients treated by diagnosis year (2010–2013) over time. Abbreviations: TNBC, triple negative breast
cancer; NAC, neoadjuvant chemotherapy; AC, adjuvant chemotherapy.
https://doi.org/10.1371/journal.pone.0222358.g004
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type database may be inaccurate. In addition, accurate assessment of clinical nodal status and/
or number of nodes prior to surgery may be inaccurate. Finally, it is now apparent that the
molecular classification of TNBC also affects clinical outcome; unfortunately, this information
is not used in routine clinical practice.[32, 33]
Conclusions
In conclusion, multiple randomized trials show that NAC is equivalent to AC. Therefore, this
current retrospective study suggesting that TNBC treated with NAC may have a worse out-
come compared to AC, should only be considered as hypothesis-generating, and highlights the
importance of determining biomarkers that can help predict those who will respond best to
NAC by achieving a pCR.
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